Hayder Abdul-Razak

Hayder Abdul-Razak has a diverse work experience spanning over 14 years. Hayder currently works as an Application Field Scientist at Mirus Bio LLC since April 2022. Prior to this, they were a Senior Scientist at Asklepios BioPharmaceutical, Inc. (AskBio) from January 2019 to March 2022, where they held a project license and was responsible for designing, conducting, and managing animal studies. Hayder also wrote project proposals and reports.

From January 2019 to March 2021, Hayder worked as a Senior Scientist at UCL. Before that, they worked at Royal Holloway, University of London from October 2014 to December 2018 as a Senior Postdoctoral Researcher. In this role, they focused on research related to Triple Trans-Splicing (TTS) AAV for Duchene muscular dystrophy and carried out in vivo and in vitro modeling.

Hayder's previous experience also includes working as a Postdoctoral Researcher at Royal Holloway, University of London from October 2012 to September 2014. Here, they worked on a therapeutic approach to combat spinal cord injury using efficient expression of Chondroitinase ABC. Hayder developed an optimal system for transgenic Chondroitinase expression from a Lentiviral vector.

Lastly, Hayder worked as a Practical Demonstrator at Royal Holloway, University of London from September 2008 to April 2012. In this role, they supervised undergraduate projects and taught various subjects related to genetics and molecular biology.

Hayder Abdul-Razak obtained a PhD degree in Gene/Genetic Therapy from the Royal Holloway, University of London. Hayder completed their doctoral studies from 2008 to 2012. In addition, Hayder Abdul-Razak has obtained certifications in PIL (Public Interest Litigation) and PPL (Private Pilot License) from the UK Home Office in April 2010 and May 2021, respectively.